IntelGenx to Join the Quebec Pavilion at BIO 2019 International Convention
23 May 2019 - 10:00PM
IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) (“IntelGenx”), leader in
pharmaceutical films, today announced that it will be joining the
Quebec Pavilion at Booth #2627 at BIO 2019 International Convention
taking place on June 3-6, 2019 in Philadelphia, PA. IntelGenx will
be promoting its contract development and manufacturing
organization (“CDMO”) service capabilities utilizing its oral film
and transdermal technologies.
VersaFilm® and VetaFilm™ are IntelGenx’s proprietary
oral drug delivery technology platforms
for human and veterinary applications,
respectively. They enable the development of oral films with
potential to improve absorption, accelerate onset of action, reduce
side effects, ease administration and improve patient
compliance. Transdermal technology is the latest addition to
IntelGenx’s drug delivery portfolio.
“We are excited to be a part of BIO International Convention – a
congregation of biotech and pharma industry leaders from around the
world” said Horst G. Zerbe, CEO of IntelGenx. “This convention
represents a great opportunity to showcase our innovative CDMO
capabilities and the tangible medical benefits our film
technologies can offer to patients.”
About IntelGenx Established in 2003, IntelGenx
is a leading oral drug delivery company primarily focused on the
development and manufacturing of innovative pharmaceutical oral
films based on its proprietary VersaFilm® and VetaFilm™ technology
platforms.
IntelGenx's highly skilled team provides comprehensive
pharmaceuticals services to pharmaceutical partners, including
R&D, analytical method development, clinical monitoring, IP and
regulatory services. IntelGenx's state-of-the-art manufacturing
facility, which was established for oral film technology platforms,
offers full service by providing lab-scale to pilot- and
commercial-scale production. More information about the company can
be found at www.intelgenx.com. Forward Looking
Statements This document may contain forward-looking
information about IntelGenx's operating results and business
prospects that involve substantial risks and uncertainties.
Statements that are not purely historical are forward-looking
statements within the meaning of Section 21E of the Securities
Exchange Act of 1934, as amended, and Section 27A of the Securities
Act of 1933, as amended. These statements include, but are not
limited to, statements about IntelGenx's plans, objectives,
expectations, strategies, intentions or other characterizations of
future events or circumstances and are generally identified by the
words "may," "expects," "anticipates," "intends," "plans,"
"believes," "seeks," "estimates," "could," "would," and similar
expressions. All forward looking statements are expressly qualified
in their entirety by this cautionary statement. Because these
forward-looking statements are subject to a number of risks and
uncertainties, IntelGenx's actual results could differ materially
from those expressed or implied by these forward-looking
statements. Factors that could cause or contribute to such
differences include, but are not limited to, those discussed under
the heading "Risk Factors" in IntelGenx's annual report on Form
10-K, filed with the United States Securities and Exchange
Commission and available at www.sec.gov, and also filed with
Canadian securities regulatory authorities at www.sedar.com.
IntelGenx assumes no obligation to update any such forward-looking
statements. Each of the TSX Venture Exchange and OTCQX has neither
approved nor disapproved the contents of this press release.
Neither TSX Venture Exchange nor its Regulation Services Provider
(as that term is defined in the policies of the TSX Venture
Exchange) accepts responsibility for the adequacy or accuracy of
this release. Source: IntelGenx Technologies Corp.
For IntelGenx:
Stephen Kilmer
Investor Relations
(514) 331-7440 ext 232
stephen@intelgenx.com
Or
Andre Godin, CPA, CA
President and CFO
IntelGenx Corp.
(514) 331-7440 ext 203
andre@intelgenx.com
Intelgenx Technologies (TSXV:IGX)
Historical Stock Chart
From Apr 2024 to May 2024
Intelgenx Technologies (TSXV:IGX)
Historical Stock Chart
From May 2023 to May 2024